The funding enables the company to develop multiple new assets that are highly competitive in the fields of oncology and immunology. Credit: THICHA SATAPITANON/Shutterstock.

Allink Biotherapeutics has completed a $42m Series A financing round to expedite the worldwide development of its bispecific antibody and antibody-drug conjugate (ADC) pipeline.

The funding will primarily support the global clinical development of its lead candidates, ALK201 and ALK202, and the enrichment of its oncology and immunology portfolio.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

It provides the necessary resources for advancing global Phase I/II clinical programmes.

The round was led by Lanchi Ventures, with contributions from new investors Legend Capital, C&D Emerging Industry Equity Investment and Yuanbio Venture Capital, and continuing support from existing shareholders Med-Fine Capital and Gaorong Ventures.

Allink will use the funds to propel the development of ALK201 and ALK202 through Phase I trials in the US, China and Australia.

The company will develop multiple new assets that are highly competitive in the fields of oncology and immunology.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

AllinkBio CEO and founder Hui Feng stated: “We are grateful for the continued support from existing shareholders and delighted to welcome new investors who recognise both our scientific excellence and capability of translating scientific findings into clinical applications.

“Their support enables us to accelerate the development of our diverse pipeline spanning multiple modalities including next-generation ADCs and bispecific antibodies targeting oncology and immunology diseases.”

The proceeds from the round will also be utilised to further develop Allink’s bispecific antibody and ADC technology platform and expand its global footprint to achieve international prominence.

Lanchi Ventures said: “AllinkBio’s exceptional execution speed and quality in advancing its lead programme from preclinical to clinical stage, led by Dr Feng, one of the leading figures in China’s biopharmaceutical industry, demonstrates the company’s high competitiveness in the field.

“AllinkBio’s innovative approach to ADC development presents a compelling opportunity in the targeted oncology therapeutics space.”